Greenwich Lifesciences Inc (NASDAQ:GLSI) — Market Cap & Net Worth
Market Cap & Net Worth: Greenwich Lifesciences Inc (GLSI)
Greenwich Lifesciences Inc (NASDAQ:GLSI) has a market capitalization of $227.51 Million ($227.51 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16146 globally and #3839 in its home market, demonstrating a 22.36% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Greenwich Lifesciences Inc's stock price $18.39 by its total outstanding shares 14678208 (14.68 Million). Also see balance sheet size of Greenwich Lifesciences Inc for a full breakdown of the balance sheet.
Greenwich Lifesciences Inc Market Cap History: 2020 to 2026
Greenwich Lifesciences Inc's market capitalization history from 2020 to 2026. Data shows growth from $535.31 Million to $269.93 Million (24.33% CAGR). Also see GLSI operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Greenwich Lifesciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #444 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1587 of 3165 |
Weight: Greenwich Lifesciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Greenwich Lifesciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Greenwich Lifesciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check GLSI live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GLSI by Market Capitalization
Companies near Greenwich Lifesciences Inc in the global market cap rankings as of September 18, 2026. Review Greenwich Lifesciences Inc (GLSI) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Greenwich Lifesciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Greenwich Lifesciences Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Greenwich Lifesciences Inc's market cap moved from $535.31 Million to $ 269.93 Million, with a yearly change of 24.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $269.93 Million | -12.47% |
| 2025 | $308.39 Million | +87.09% |
| 2024 | $164.84 Million | +6.75% |
| 2023 | $154.41 Million | -30.79% |
| 2022 | $223.11 Million | -37.53% |
| 2021 | $357.12 Million | -33.29% |
| 2020 | $535.31 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Greenwich Lifesciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $227.51 Million USD |
| MoneyControl | $227.51 Million USD |
| MarketWatch | $227.51 Million USD |
| marketcap.company | $227.51 Million USD |
| Reuters | $227.51 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Ph… Read more